JP7186400B2 - ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 - Google Patents

ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 Download PDF

Info

Publication number
JP7186400B2
JP7186400B2 JP2019531589A JP2019531589A JP7186400B2 JP 7186400 B2 JP7186400 B2 JP 7186400B2 JP 2019531589 A JP2019531589 A JP 2019531589A JP 2019531589 A JP2019531589 A JP 2019531589A JP 7186400 B2 JP7186400 B2 JP 7186400B2
Authority
JP
Japan
Prior art keywords
protein
item
sequence
selenocysteine
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502104A5 (enExample
JP2020502104A (ja
Inventor
ダニエル ジェイ． マンデル，
ロス タイヤー，
アンドリュー ディー． エリントン，
ピーター ベンジャミン ストレンジズ，
クリストファー ジェイ． グレッグ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2020502104A publication Critical patent/JP2020502104A/ja
Publication of JP2020502104A5 publication Critical patent/JP2020502104A5/ja
Priority to JP2022184852A priority Critical patent/JP7378106B2/ja
Application granted granted Critical
Publication of JP7186400B2 publication Critical patent/JP7186400B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
JP2019531589A 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造 Active JP7186400B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022184852A JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381316P 2016-08-30 2016-08-30
US62/381,316 2016-08-30
US201762537986P 2017-07-28 2017-07-28
US62/537,986 2017-07-28
PCT/US2017/049354 WO2018045018A1 (en) 2016-08-30 2017-08-30 Production of seleno-biologics in genomically recoded organisms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022184852A Division JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Publications (3)

Publication Number Publication Date
JP2020502104A JP2020502104A (ja) 2020-01-23
JP2020502104A5 JP2020502104A5 (enExample) 2020-10-08
JP7186400B2 true JP7186400B2 (ja) 2022-12-09

Family

ID=61301655

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531589A Active JP7186400B2 (ja) 2016-08-30 2017-08-30 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022184852A Active JP7378106B2 (ja) 2016-08-30 2022-11-18 ゲノム的に再コードした生物におけるセレノ－生物製剤の製造

Country Status (6)

Country Link
US (1) US11492650B2 (enExample)
EP (1) EP3506945A4 (enExample)
JP (2) JP7186400B2 (enExample)
CN (1) CN109803679A (enExample)
CA (1) CA3034701A1 (enExample)
WO (1) WO2018045018A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
CN109844105A (zh) 2016-07-11 2019-06-04 得克萨斯州大学系统董事会 包含硒代半胱氨酸的重组多肽及其产生方法
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
JP7384906B2 (ja) * 2018-07-09 2023-11-21 ジーアールオー・バイオサイエンシズ・インコーポレイテッド 非標準アミノ酸含有組成物とその使用
CN114144426A (zh) * 2019-04-19 2022-03-04 印地安纳大学理事会 餐时或基础胰岛素类似物通过内部二硒桥的稳定化
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
JP2023545520A (ja) 2020-10-14 2023-10-30 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患を治療するための組成物及び方法
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
CN118076644A (zh) * 2021-09-30 2024-05-24 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504187A (ja) 2007-11-20 2011-02-03 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849417B1 (en) * 1998-04-06 2005-02-01 The United States Of America As Represented By The Department Of Health And Human Services Mammalian selenoprotein differentially expressed in tumor cells
AU6987200A (en) 1999-08-16 2001-03-13 Karolinska Innovations Ab Methods and means for selenoprotein expression
WO2007075438A2 (en) * 2005-12-15 2007-07-05 Codon Devices, Inc. Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
WO2009043051A2 (en) 2007-09-27 2009-04-02 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
AU2012216723B2 (en) * 2007-11-20 2014-08-28 Ambrx, Inc. Modified insulin polypeptides and their uses
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
US20140024592A1 (en) * 2010-09-08 2014-01-23 Howard Florey Institute Of Experimental Physiology And Medicine Modified Relaxin Polypeptides
MX2013008736A (es) * 2011-01-28 2013-11-22 Ca Nat Research Council Diseño de dominios de inmunoglobulina.
DK2717898T3 (en) 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
US10240158B2 (en) 2011-07-11 2019-03-26 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10876142B2 (en) 2011-07-11 2020-12-29 Yale University Compositions and methods for making selenocysteine containing polypeptides
EP2968552B1 (en) 2013-03-14 2020-03-11 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
US20150050682A1 (en) 2013-08-15 2015-02-19 University Of Vermont And State Agricultural College Direct assay of thioredoxin reductase activity
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
US10118950B2 (en) 2014-08-30 2018-11-06 Northwestern University Platforms for cell-free protein synthesis comprising extracts from genomically recoded E. coli strains having genetic knock-out mutations in release factor 1 (RF-1) and endA
WO2016172269A2 (en) * 2015-04-20 2016-10-27 University Of Utah Research Foundation Insulin analogs having shortened b chain peptides and associated methods
CN105111304B (zh) * 2015-09-30 2018-12-14 山东阿华生物药业有限公司 重组人胰岛素前体的纯化和酶切转换方法
US10557160B2 (en) 2015-12-15 2020-02-11 Board Of Regents, The University Of Texas System Transgenic bacteria with expanded amino acid usage and nucleic acid molecules for use in the same
CN109844105A (zh) * 2016-07-11 2019-06-04 得克萨斯州大学系统董事会 包含硒代半胱氨酸的重组多肽及其产生方法
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs
IL264330B2 (en) * 2016-07-22 2024-05-01 Univ Utah Res Found An insulin analog, pharmaceutical composition comprising it and its uses
CN114144426A (zh) 2019-04-19 2022-03-04 印地安纳大学理事会 餐时或基础胰岛素类似物通过内部二硒桥的稳定化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011504187A (ja) 2007-11-20 2011-02-03 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
52nd Japanese Peptide Symposium 第５２回ペプチド討論会 講演要旨集，2015年，Vol.52，P.78, No.P-021

Also Published As

Publication number Publication date
JP7378106B2 (ja) 2023-11-13
EP3506945A1 (en) 2019-07-10
JP2023015347A (ja) 2023-01-31
EP3506945A4 (en) 2020-07-15
WO2018045018A1 (en) 2018-03-08
WO2018045018A8 (en) 2018-05-11
CN109803679A (zh) 2019-05-24
CA3034701A1 (en) 2018-03-08
US11492650B2 (en) 2022-11-08
US20190194713A1 (en) 2019-06-27
JP2020502104A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
JP7378106B2 (ja) ゲノム的に再コードした生物におけるセレノ－生物製剤の製造
US20220213500A1 (en) Expression Process
Peternel et al. Engineering inclusion bodies for non denaturing extraction of functional proteins
JP7598243B2 (ja) 抗体発現を最適化するための方法
AU2002217505B2 (en) Process for producing recombinant protein and fused protein
CN103168046A (zh) 用于加工包涵体的方法
Vyas et al. Clinical manufacturing of recombinant human interleukin 15. I. Production cell line development and protein expression in E. coli with stop codon optimization
AU2004234282B2 (en) Chaperonine-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release preparation and method of producing antibody against target protein
de Araujo et al. Strategies for over-expression and purification of recombinant full length STAT5B in Escherichia coli
Yurkova et al. Production of a toxic polypeptide as a fusion inside GroEL cavity
HK40007802A (en) Production of seleno-biologics in genomically recoded organisms
JP2004081199A (ja) 組換え抗体の製造方法
JP5733693B2 (ja) 組換え型ポリペプチドの製造方法
Shayfutdinov et al. Optimization of RNA Structure Leads to Increased Biosynthesis of E. coli L-asparaginase when its Gene is Overexpressed
JPWO2004031243A1 (ja) タンパク質ポリマー及びその製造方法
KR20250167672A (ko) 단일 사슬 항체 및 그 체외 합성 시스템과 용도
Galiardi Split Intein Applications for Downstream Purification and Protein Conjugation
Bartlow Design of Escherichia coli host strains for improved recombinant protein purification: An approach that bridges the upstream and downstream realms of bioprocessing
JP2001294599A (ja) 組み換えｂ型肝炎ウィルス表面抗原

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210903

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221021

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7186400

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250